

Barbara Altieri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8433764/publications.pdf>

Version: 2024-02-01

92
papers

1,821
citations

304368

22
h-index

315357

38
g-index

104
all docs

104
docs citations

104
times ranked

2373
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. <i>Endocrine</i> , 2022, 75, 623-634.	1.1	6
2	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. <i>European Journal of Endocrinology</i> , 2022, 186, 25-36.	1.9	41
3	Canine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies. <i>Translational Oncology</i> , 2022, 15, 101269.	1.7	8
4	Sex differences in carcinoid syndrome: A gap to be closed. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 659-669.	2.6	7
5	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 499-508.	5.5	55
6	FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma. <i>Endocrine</i> , 2022, 77, 411-418.	1.1	6
7	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 511-525.	2.6	13
8	Circulating microRNA Expression in Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 620012.	1.5	11
9	Chronotype and cardio metabolic health in obesity: does nutrition matter?. <i>International Journal of Food Sciences and Nutrition</i> , 2021, 72, 892-900.	1.3	22
10	Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 649496.	1.5	27
11	Epithelial and Mesenchymal Markers in Adrenocortical Tissues: How Mesenchymal Are Adrenocortical Tissues?. <i>Cancers</i> , 2021, 13, 1736.	1.7	5
12	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	1.1	14
13	Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study. <i>Journal of the Endocrine Society</i> , 2021, 5, A165-A166.	0.1	1
14	Evaluation of the Molecular Pathogenesis of Adrenocortical Tumors by Whole-Genome Sequencing. <i>Journal of the Endocrine Society</i> , 2021, 5, A68-A68.	0.1	0
15	Case Report: Consecutive Adrenal Cushing's Syndrome and Cushing's Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. <i>Frontiers in Endocrinology</i> , 2021, 12, 731579.	1.5	5
16	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. <i>Frontiers in Endocrinology</i> , 2021, 12, 705214.	1.5	15
17	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. <i>Cancers</i> , 2021, 13, 4671.	1.7	12
18	Clinical and penile Doppler outcomes using a modified, tourniquet free, Nesbit plication for severe Peyronie's disease. <i>Translational Andrology and Urology</i> , 2021, 10, 2857-2870.	0.6	0

#	ARTICLE	IF	CITATIONS
19	The Importance of Being a "Lark"™ in Post-Menopausal Women with Obesity: A Ploy to Prevent Type 2 Diabetes Mellitus?. <i>Nutrients</i> , 2021, 13, 3762.	1.7	17
20	Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. <i>Clinical and Translational Medicine</i> , 2021, 11, e630.	1.7	4
21	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	1.7	5
22	Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy. <i>Minerva Endocrinology</i> , 2021, , .	0.6	2
23	Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications. <i>Frontiers in Endocrinology</i> , 2021, 12, 795116.	1.5	2
24	Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 78-84.	1.8	39
25	Vitamin D testing: advantages and limits of the current assays. <i>European Journal of Clinical Nutrition</i> , 2020, 74, 231-247.	1.3	81
26	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4459-e4473.	1.8	24
27	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 597878.	1.5	18
28	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. <i>Frontiers in Endocrinology</i> , 2020, 11, 219.	1.5	23
29	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
30	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020, 69, 441-450.	1.1	26
31	Next-generation therapies for adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101434.	2.2	61
32	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. <i>Cancers</i> , 2020, 12, 359.	1.7	23
33	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	1.7	28
34	Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors. <i>Nutrients</i> , 2020, 12, 1021.	1.7	17
35	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2642-2653.	1.8	18
36	ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus. <i>European Journal of Endocrinology</i> , 2020, 183, R197-R215.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Bone metabolism, bone mass and structural integrity profile in professional male football players. <i>Journal of Sports Medicine and Physical Fitness</i> , 2020, 60, 912-918.	0.4	5
38	SUN-LB22 PLK1 as a New Treatment Target for Adrenocortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	1
39	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	1.0	31
40	Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. <i>Cancers</i> , 2019, 11, 1332.	1.7	28
41	Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. <i>International Journal of Obesity Supplements</i> , 2019, 9, 32-49.	12.5	24
42	Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: a pilot study. <i>Hormones</i> , 2019, 18, 75-84.	0.9	37
43	Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2019, 17, 610-617.	0.8	22
44	SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
45	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2018, 178, 181-188.	1.9	15
46	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4511-4523.	1.8	92
47	An Italian Survey of Compliance With Major Guidelines for L-Thyroxine of Primary Hypothyroidism. <i>Endocrine Practice</i> , 2018, 24, 419-428.	1.1	13
48	Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness. <i>Nutrients</i> , 2018, 10, 1854.	1.7	61
49	Nutrition and neuroendocrine tumors: An update of the literature. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 159-167.	2.6	38
50	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. <i>Endocrine</i> , 2018, 62, 506-516.	1.1	11
51	The role of insulin-like growth factor system in the adrenocortical tumors. <i>Minerva Endocrinologica</i> , 2018, 44, 43-57.	1.7	25
52	Vitamin D and pancreas: The role of sunshine vitamin in the pathogenesis of diabetes mellitus and pancreatic cancer. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3472-3488.	5.4	77
53	Shedding new light on female fertility: The role of vitamin D. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 273-283.	2.6	98
54	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 335-346.	2.6	134

#	ARTICLE	IF	CITATIONS
55	Current evidence on vitamin D deficiency and kidney transplant: What's new?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 323-334.	2.6	15
56	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4323-4332.	1.8	79
57	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3491-3498.	1.8	33
58	Adrenal disorders: Is there Any role for vitamin D?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 355-362.	2.6	17
59	Vitamin D and chronic diseases: the current state of the art. <i>Archives of Toxicology</i> , 2017, 91, 97-107.	1.9	108
60	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. <i>Oncotarget</i> , 2017, 8, 9323-9338.	0.8	27
61	Leydig Cell Tumour and Giant Adrenal Myelolipoma Associated with Adrenogenital Syndrome: A Case Report with a Review of the Literature. <i>Urologia</i> , 2016, 83, 43-48.	0.3	6
62	Adrenocortical tumors and insulin resistance: What is the first step?. <i>International Journal of Cancer</i> , 2016, 138, 2785-2794.	2.3	29
63	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. <i>Endocrine-Related Cancer</i> , 2015, 22, 531-543.	1.6	27
64	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. <i>PLoS ONE</i> , 2014, 9, e105855.	1.1	41
65	Chronic low-dose glucocorticoid inhalatory therapy as a cause of bone loss in a young man: case report. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 199-202.	1.0	6
66	Low bone mineral density in a growth hormone deficient (GHD) adolescent. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 203-5.	1.0	5
67	Adverse events of mitotane treatment in patients with adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
68	Circulating cell-free DNA for prognostication and disease surveillance in adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
69	Targeted molecular analysis in adrenocortical carcinomas: a strategy towards improved personalized prognostication. <i>Endocrine Abstracts</i> , 0, , .	0.0	2
70	Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
71	The Notch ligand Jagged1 is up-regulated in adrenocortical carcinomas and is associated with a favourable clinical outcome. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
72	Inhibitor of apoptosis protein livin/BIRC7 in adrenocortical tumours. <i>Endocrine Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
73	CYP2W1*6 polymorphism as a potential predictive marker of sensitivity to mitotane treatment in adrenocortical carcinoma.. Endocrine Abstracts, 0, , .	0.0	0
74	Epithelial to mesenchymal transition in adrenocortical tumours: focus on FGF-FGFR pathway and c-MET. Endocrine Abstracts, 0, , .	0.0	0
75	Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study. Endocrine Abstracts, 0, , .	0.0	0
76	Mesenchymal tissue markers as potential drug targets in adrenocortical tumours. Endocrine Abstracts, 0, , .	0.0	0
77	Targeted molecular analysis in adrenocortical carcinomas: a way towards improved personalized prognostication. Endocrine Abstracts, 0, , .	0.0	1
78	New cancer drug targets identified in adrenocortical carcinoma through gene expression profiling. Endocrine Abstracts, 0, , .	0.0	1
79	Germline CYP2W1*6 and CYP2B6*6 polymorphisms as predicting markers of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicentric ENSAT study. Endocrine Abstracts, 0, , .	0.0	0
80	Cyclin dependent kinase 4 as promising drug target in adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
81	Neuroendocrine neoplasms (NEN) arising in uncommon sites: epidemiological and clinical features. Endocrine Abstracts, 0, , .	0.0	0
82	Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
83	Vitamin D deficiency is a predictor marker of tumor aggressiveness in sporadic and MEN1-related well-differentiated, low-grade GEP-NET. Endocrine Abstracts, 0, , .	0.0	0
84	Lanreotide therapy vs wait-and-see in patients with pancreatic neuroendocrine tumors. Endocrine Abstracts, 0, , .	0.0	1
85	PLK1 inhibitors as potential new treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
86	Sporadic neuroendocrine neoplasms in young-adult patients: Differences in natural history, prognosis and treatment compared to adult-elderly patients. Endocrine Abstracts, 0, , .	0.0	0
87	Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study. Endocrine Abstracts, 0, , .	0.0	0
88	RNA-sequencing of adrenocortical tumors reveals novel pathogenetic insights. Endocrine Abstracts, 0, , .	0.0	1
89	Adverse events associated to mitotane treatment in patients with adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
90	Consecutive adrenal cushing's syndrome and cushing's disease in a patient with somatic CTNNB1, USP8, and NR3c1 mutations. Endocrine Abstracts, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
91	PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
92	Circulating cell-free DNA-based biomarkers as a tool for disease surveillance in adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0